CABA

NASDAQ open

Cabaletta Bio

1.03 USD
▲+0.01+1.49%
盘后 1.26 0.00%
2026-11-20
市值
$201.94M
市盈率
—
EPS
-1.37
股息率
—
52 周区间
0.98 – 4.23
成交量
319.12K
Beta
3.54
目标价
11.75
52W 低 0.9852W 高 4.23
价格走势

公司简介

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero...